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http://dx.doi.org/10.1016/j.jfma.201Although exact statistics are lacking, body modifications for cosmetic purposes are performed
in many countries. The commonest forms include tattooing, body piercing, and breast and
facial augmentation using implants or injectable fillers. Liposuction and, to a lesser extent,
mesotherapy are also practiced in many countries. Infective complications of these procedures
include local infections, transmission of bloodborne pathogens (viral hepatitis and human
immunodeficiency virus), and distant infections such as infective endocarditis. Presence of
foreign bodies, long healing time of piercing wounds, and poor compliance with infection
control practices of some practitioners all predispose the recipients to infections. Apart from
the endogenous microbial flora of the skin and mucosae, atypical mycobacteria, especially the
rapid growers, have emerged as some of the most important pathogens in such settings.
Outbreaks of infection are commonly reported. We hereby review the current knowledge of
the topic with specific focus on infections associated with tattooing, body piercing, breast
augmentation, mesotherapy, liposuction, and tissue filler injections. Greater awareness among
consumers and health-care professionals, as well as more stringent regulations by the health
authorities, is essential to minimize the health risks arising from these procedures.
Copyright ª 2012, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
Body modification or body art for nontherapeutic purposes
encompasses a vast variety of procedures, ranging from
common procedures such as tattooing, body piercing,t of Microbiology, Research
y, Faculty of Medicine, The
.-Y. Yuen).
ight ª 2012, Elsevier Taiwan LLC
2.10.016subdermal and transdermal implantation, and breast
augmentation, to more drastic procedures such as tongue
splitting, genital modification, and gender reassignment
surgery. There are few formal statistics on the prevalence
of body modification in most parts of the world. In a study
of undergraduates in the United States, the prevalence of
body piercing and tattooing was found to be 51% and 23%,
respectively.1 In Europe, the prevalence of tattooing has
been reported to be 6e12% in different studies, and that of
body piercing about 20% in some studies.2,3 Similarly, the
incidence or risk of infective complications following these& Formosan Medical Association. All rights reserved.
668 S.S.-Y. Wong et al.procedures is unknown. This is due to the fact that there is
no information on the denominator of persons who have
received these procedures, and that cases reported in the
literature tend to be isolated case reports or well-
documented outbreaks. The vast majority of individuals
who went for tattooing or body piercing had not considered
the potential health risks prior to the procedures.4 In most
countries, practitioners of body modification and body art
parlors are not strictly regulated by law, and therefore
stringent adherence to the recommended infection control
practice is sometimes doubtful. Persons embracing body
modifications sometimes also engage in other risky behav-
iors such as illicit drug use and alcoholism, which may
predispose them to other infective complications.5e7
Body modification procedures can be complicated by
local pain, inflammation, infection. Circumstances predis-
posing individuals to infections after body modification are
manifold. Various microbial and environmental factors
contribute to the transmission of microbial pathogens
during body modification procedures. Since these proce-
dures inevitably involve breaches in the skin or mucosae,
pathogens can be introduced from the normal flora colo-
nizing the surfaces or from exogenous microbes such as
contaminated instruments, jewelry, and disinfectants.
These infecting organisms can sometimes cause infections
in distant organs. Organisms such as Pseudomonas aerugi-
nosa and atypical mycobacteria are ubiquitous in the
environment. Their resistance to and ability to contaminate
low-level disinfectants and antiseptics have been well
documented.8 Other major concerns are bloodborne
infections such as viral hepatitis and human immunodefi-
ciency virus (HIV) infection. High-level viremia can be
encountered in patients with hepatitis B virus (HBV) and HIV
infections, and even minute contaminations with their
blood and body fluids can result in infections if disinfection
of the environment and instruments is inadequate. The
prolonged survival of hepatitis C virus (HCV) in the envi-
ronment may also contribute to its transmission under such
circumstances.9
In many countries, body modification procedures per-
formed in parlors are not subjected to strict hygienic
regulations. The majority of these “minor” procedures are
performed in commercial premises or by unlicensed
personnel, sometimes without strict adherence to infection
control guidelines. Sterilization and disinfection of instru-
ments between clients, choice and maintenance of chem-
ical disinfectants and antiseptics, and adoption of
a particular infection control practice (such as mainte-
nance of a sterile field, prevention of cross-contamination,
and disposal of biohazardous wastes) often depend on the
conscientiousness of the premise owners and operators. A
number of outbreaks related to such procedures have been
reported in recent years (Table 1).2,10e44 As a form of
“medical tourism”, consumers are often receiving body
modifications in overseas countries where the costs are
lower. Some of these medical tourism destinations and
institutions may have less stringent levels of infection
control, which might have explained the occurrence of
infection outbreaks among some of the recipients.44 A more
recent concern over medical tourism is related to the
country-to-country transfer of multiresistant bacteria. For
example, many early cases of infections due to New Delhimetallo-beta-lactamase-producing Enterobacteriaceae had
received prior medical care in the Indian subcontinent.45
Tattooing
In the process of tattooing, colored inks are introduced
mechanically into the skin dermis by electrically driven
needles. Local and systemic health problems are common
after tattooing, which persist even for weeks after the
procedure.2 Infective complications may result from the
cross-contamination of inadequately sterilized equipment
and contaminated tattoo inks. Reported infections, which
were sometimes associated with outbreaks in the tattoo
recipients, include tuberculosis (lupus vulgaris), leprosy,
verruca vulgaris and verruca plana due to human papillo-
maviruses, zygomycosis, community-associated methicillin-
resistant Staphylococcus aureus, and atypical mycobac-
teria, especially the rapid growers.10e13,46e53 Noninfective
causes of local skin reactions to tattoos, including allergic,
granulomatous, and lichenoid reactions or coincidental
lesions such as malignancies, should also be considered as
differential diagnoses.54
Exposure to bloodborne pathogens poses a major infec-
tious risk to persons receiving tattoos. Although syphilis
used to be a common infection transmitted during tattoo-
ing, it is relatively uncommon nowadays. One of the largest
outbreaks of HBV infection affected 34 persons of whom 31
were tattooed by one artist and three were secondary
cases.55 Epidemiological studies have shown tattooing to be
a risk factor for HCV infection, and a dose-related response
was noted.56,57 In contrast to HCV infection acquired from
blood product transfusion, that acquired from tattooing is
often subclinical, probably reflecting the smaller inoculum
of viruses transferred in such settings.58 Tattooing has been
shown to be a risk factor for HIV infection in some studies,
but not in others, possibly due to the confounding effects of
various at-risk behaviors in this group of individuals.59e61
However, a recent case of HIV infection in an Australian
tourist after receiving tattoos in Bali again raised the
possibility of HIV transmission in such settings.62
Body piercing
Body piercing involves puncturing of the skin or mucosae
with subsequent insertion of foreign bodies, such as rings,
bars, or other jewelries. In some procedures, the cartilage
is also pierced, as in case of “high piercing” of the ear
involving the cartilage of the pinna. Common sites of
piercing include ears, eyebrows, lips, navel, nipples, geni-
talia, nose, tongue, and other parts of the oral mucosa. As
in the case of tattooing, body piercing can be associated
with transmission of bloodborne pathogens.63e65 Local
inoculation of pathogens has likewise resulted in the
transmission of tuberculosis (lupus vulgaris) and
tetanus.66,67 Bacterial infections of the skin and soft tissues
tend to be commoner in body piercing than in tattooing
because of the greater degree of tissue damage, presence
of deeper wounds, and placement of foreign bodies
(jewelry) in the wounds in the former case. One important
contributing factor is the long healing time of the wound
after piercing, which may take up to 6e9 months in some
Table 1 Clusters, outbreaks, or case series of infections associated with body modification procedures.
Procedure Year Location Number of patients
with infective
complications
Type(s) of infection Organism(s)
involved
Important
epidemiological
characteristics
Reference
Tattooing NA Germany 7 Skin infection,
granulomatous and
purulent
Mycobacterium spp.,
possibly related to
Mycobacterium
haemophilum
Eyebrow tattoos by the
same tattooist using
Chinese tattoo ink;
onset days to weeks
after tattooing; all had
local lymphadenopathy
10
Tattooing 2004e2005 Ohio, Kentucky,
Vermont, USA
44 Skin abscesses Community-associated
methicillin-resistant
Staphylococcus aureus
44 recipients in six
unlinked clusters from
13 unlicensed
tattooists in three
states; onset within 4
e22 d; skin lesions
were present in some
tattooists
11
Tattooing 2007e2008 Germany, Austria,
Switzerland
0.4% Pustular skin lesions NA 5997 individuals, as
found from the Internet
survey
2
1.0e1.2% Fever
Tattooing 2007e2008 Minnesota, USA 6 Skin infection Mycobacterium
chelonae
All received tattoos by
the same tattooist;
onset within 1e2 wk;
environmental cultures
negative; original ink
not available for
culture
12
Tattooing 2011 USA 14 confirmed cases, 4
probable cases, 1
suspected case
Skin infection M. chelonae,
Mycobacterium
abscessus
M. chelonae also
isolated from
unopened bottles of
tattoo ink, with
identical PFGE patterns
as patients’ isolates
13
Nipple piercing Literature
review
Literature
review
12 Breast abscess Streptococcus
pyogenes,
Streptococcus
agalactiae, coagulase-
negative staphylococci,
anaerobes, M.
abscessus,
Mycobacterium
fortuitum
Incubation period 2 wk
to 12 mo
14
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Table 1 (continued )
Procedure Year Location Number of patients
with infective
complications
Type(s) of infection Organism(s)
involved
Important
epidemiological
characteristics
Reference
Ear piercing 2000 Oregon, USA 7 confirmed, 18
suspected cases
Auricular chondritis
and ear lobe infection
P. aeruginosa, S.
aureus from one case
with ear lobe infection
118 customers of a
jewelry kiosk
interviewed; improper
practices noted;
P. aeruginosa isolated
from some of the staff
and from an atomizer
solution containing
a mixture of
quaternary ammonium
and phenolic
disinfectant, which had
been refilled
repeatedly; cartilage
piercing associated
with a higher risk of
infection
15
Oral piercing 1966e2009 Literature review 18 Infective endocarditis
(8), Ludwig’s angina
(2), tongue abscess (1),
glossitis (1), cephalic
tetanus (1), cerebellar
abscess (1),
lymphadenitis (2),
sialadenitis (1), dental
abscess with neck
extension (1),
chorioamnionitis (1)
Endocarditis cases:
Neisseria mucosa (1),
Haemophilus
aphrophilus (1),
S. aureus (2), oral
streptococci (3),
Gemella (1); other
infections: oral
streptococci, Eikenella
corrodens,
Lactobacillus,
anaerobes,
Actinomyces
No fatal cases reported 16
Oral piercing 2002e2003 Ghent, Belgium 13 History of symptoms
suggestive of infection
NA 50 persons attending a
dental clinic surveyed;
average duration of
oral piercing 12.6 mo
17
Oral piercing 2002e2008 Emergency
departments, USA
9926 Infection at piercing
site
NA 24,459 with oral
piercing-related
injuries
18
Ear piercing 2003 New York, USA 15 Auricular chondritis P. aeruginosa Outbreak associated
with the same piercing
facility; incubation
19
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period 1e13 d; risk
factors for infection:
helix piercing and use
of aftercare solution;
P. aeruginosa isolated
from aftercare solution
containing
benzalkonium chloride
Oral piercing 2005 Strasbourg, France 6 Any infective
complication
NA Questionnaire survey of
201 individuals with
current oral and
perioral piercings only
20
Oral piercing 2009 Bele´m, Brazil 16 Purulent discharge NA 39 university students
with oral piercing
21
Breast implants,
cosmetic and
reconstructive
1964e1991 Minnesota, USA 19 patients, 21 breasts Wound infection NA 749 cases recruited
from one institute:
cosmetic 532,
reconstructive 125,
prophylaxis 92; overall
complication rate:
reconstructive
> prophylactic
> cosmetic surgery
22
Breast
augmentation
and face lift
1985 USA 8 Surgical wound
infection
Culture positive for
M. abscessus in five
cases
Contaminated gentian
violet solution used for
skin marking by the
same surgeon; also
culture positive for
M. abscessus
23
Breast implants,
cosmetic
2003 Israel 15 Surgical site infection Mycobacterium
jacuzzii
Associated with one
single medical center
and surgeon;
incubation period 9e52
d. Same organism
isolated from his
whirlpool and hair-
bearing regions of the
skin
24
Breast implants,
cosmetic
1999e2007 Denmark 63/80, 67/81, 35/38
women/implants
within 30 d, 3 y, and
5 y, respectively.
Wound infection and
periprosthetic
infection
NA Primary cosmetic
implantation, 5130/
10,252 women/
implants; primary
implantation for breast
anomalies, 243/388
women/implants
25
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Table 1 (continued )
Procedure Year Location Number of patients
with infective
complications
Type(s) of infection Organism(s)
involved
Important
epidemiological
characteristics
Reference
Breast implants,
cosmetic
1999e2002 Denmark 6/6 patients/implants
(initial); 4/5 patients/
implants (subsequent)
Wound infection NA Cohort with 1946
persons, 3390 primary
implantations, 454
subsequent
implantations
26
2/2 patients/ implants
(initial); 0/0 patients/
implants (subsequent)
Periprosthetic
infection
Breast implants,
cosmetic
1999e2004 Birmingham, UK 33 Surgical site infection NA 3002 women; onset of
infection 22  12.8 d;
Reduced risks
associated with Mentor
prostheses, and use of
antiseptics and
antibiotics; increased
risk associated with use
of drains
27
Breast implants,
reconstructive
2005e2007 Genoa, Italy 16 Implant-associated
infections
S. aureus (4),
coagulase-negative
staphylococci (2),
S. agalactiae (1),
Serratia marcescens
(2), Enterobacter
cloacae (1),
P. aeruginosa (3),
Acinetobacter
baumannii (1), culture
negative (4)
240 breast cancer
patients reviewed;
onset 2e239 d; higher
risk in patients
receiving radiotherapy
after surgery
28
Breast implants,
reconstructive
1994e1998 Michigan,
Pennsylvania,
Louisiana, USA;
Ontario, Canada
28/21/12 patients in
implants/pedicle
TRAM/free TRAM flap
groups, respectively
Surgical site infections NA 325 patients:
expander/implants, 79
patients; pedicle TRAM
flaps, 179 patients;
free TRAM flaps, 67
patients
29
Breast implants,
reconstructive
1999e2003 Denmark 29/30 patients/
implants (initial); 13/
13 patients/implants
(subsequent)
Wound infection NA Cohort with 574/901
patients/implants;
407/484 patients/
implants enrolled at
initial implantation,
302/417 patients/
implants enrolled at
30
14/16 patients/
implants (initial); 3/3
patients/ implants
Periprosthetic
infection
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subsequent
implantation
(subsequent)
Injected PAAG
augmentation
mammoplasty
1997e? China 2 Infection NA 12 persons presenting
with complications
after injection
31
Injected PAAG
augmentation
mammoplasty
1999e2003 China 8 Infection NA 30 persons presenting
with complications
after injection
32
Injected PAAG
augmentation
mammoplasty
2000e2003 China 6 Infection NA 42 persons presenting
with complications
after injection
33
Injected PAAG
augmentation
mammoplasty
2005e2008 China 6 Infection NA 235 persons presenting
with complications
after injection
34
Injected PAAG
soft tissue
augmentation
1997e2008 Iran 11 Infection and abscesses NA 98 persons presenting
with complications
after injection to face
(73), breasts (16), and
buttocks and legs (9)
35
Injected PAAG
for facial
augmentation
2001e2005 15 sites in Europe 4 Infection NA 251 persons enrolled 36
Mesotherapy 2004e2005 Colombia 15 Skin infection M. chelonae (5),
nontuberculous
mycobacteria (6),
culture negative (4)
Incubation period 1e12
wk
37
Mesotherapy 2004e2005 Colombia 70 Skin infection Culture positive in 29
cases: M. chelonae
(26), M. abscessus (2),
M. fortuitum (1)
Incubation period 8e60
d; 66% of the cases
received mesotherapy
from one practitioner
38
Mesotherapy 2004e2005 Peru 35 Skin infection Culture positive for
M. chelonae in four
cases
Median incubation
period 16 d;
epidemiologically
linked to two
mesotherapy training
courses; M. chelonae
isolated from
a procaine vial
39
Mesotherapy 2005 District of
Columbia, USA
14 Skin inflammation,
ulceration, and
drainage at sites of
injection
Culture positive for
M. chelonae in one case
All received injections
from the same person
at a private home;
multiple breaches in
safe injection practices
reported
40
(continued on next page )
In
fe
ctio
n
s
a
sso
cia
te
d
w
ith
b
o
d
y
m
o
d
ifi
ca
tio
n
673
Table 1 (continued )
Procedure Year Location Number of patients
with infective
complications
Type(s) of infection Organism(s)
involved
Important
epidemiological
characteristics
Reference
Mesotherapy 2006e2007 France 16 Skin infection M. chelonae and/or
Mycobacterium
frederiksbergense
105 patients exposed,
48 responded and
examined; incubation
period 7e152 d;
inappropriate cleansing
of equipment with tap
water; 100% similarity
between patient
isolates and tap water
isolates of M. chelonae
by PFGE
41
Mesotherapy 2006e2007 France 16 Skin infection Culture positive in 12
cases: M. chelonae (11)
and/or
M. frederiksbergense
(2)
All received
mesotherapy from the
same practitioner;
incubation period 7
e152 d; M. chelonae
identified from tap
water
42
Mesotherapy 2007 La Rioja, Spain 39 Skin infection Culture positive for
M. fortuitum in 12
cases
138 persons received
mesotherapy by a
single practitioner in
the same salon;
incubation period
1e254 d
43
Liposuction and
other cosmetic
surgeries
2003e2004 Eastern USA, ex
Dominican Republic
20 Abdominal wall wound
infections, breast
implant infections
M. abscessus Received breast
augmentation and
liposuction at a clinic in
Dominican Republic;
45% of cases had
procedures in the same
clinic; incubation
period 2e18 wk
44
NA Z not available; PAAG Z polyacrylamide hydrogel; PFGE Z pulsed-field gel electrophoresis; TRAM Z transverse rectus abdominis musculocutaneous.
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Infections associated with body modification 675locations.68,69 Ear piercing, for example, may lead to
infection and purulent discharge in 11e24% of the individ-
uals (Fig. 1).70,71 The commonest pathogens involved are
S. aureus, Streptococcus pyogenes, and P. aeruginosa.
Local abscess formation, toxic shock syndrome, and Four-
nier’s gangrene (after genital piercing) have been reported
to occur after piercing.14,72,73 Auricular chondritis caused
by P. aeruginosa is particularly difficult to manage, and high
piercing of the ear pinna is a definite risk factor for the
development of infection.15,19,74e77 Failure to disinfect the
equipment properly and use of contaminated disinfectants
have been found to be associated with P. aeruginosa
chondritis after high piercing.15,19 The cartilage is an
avascular structure; its infection is extremely problematic
because systemically administered antibiotics may not
penetrate sufficiently well into the site of infection.
Substantial necrosis and destruction of the cartilage can be
followed by deformities that require extensive recon-
structive surgery to correct.78 Infections caused by rapidly
growing mycobacteria following body piercing have also
been reported.79,80
Intraoral piercing poses some unique infective problems.
The oral mucosa is heavily colonized by normal flora, and
therefore invasive infections such as intraoral abscesses
and severe head and neck infections such as Lemierre’s
syndrome can occur readily following oral piercing. Infec-
tive endocarditis is a major complication following piercing
of the mouth and skin. Reported pathogens include
S. aureus, coagulase-negative staphylococci, viridansFigure 1 Cellulitis around the earlobe after ear piercing.streptococci, S. pyogenes, Neisseria mucosa, Haemophilus
aphrophilus, H. parainfluenzae, and Gemella, all of which
are part of the normal flora of the skin and
oropharynx.16,81e86 Although current guidelines on antibi-
otic prophylaxis against infective endocarditis do not
specifically address body piercing, this prophylaxis has been
suggested to be beneficial for intraoral piercing.87 Never-
theless, the actual benefit of single doses of antibiotics can
be nullified by the prolonged presence of mucosal wounds
and foreign bodies in such settings.Breast augmentation procedures
Breast implants are used for either reconstructive surgery
or cosmetic purposes. The practice of injecting paraffin or
silicone for this purpose is now obsolete because of the
severe adverse reactions associated with it, such as mas-
titits, chronic inflammation (paraffinoma and siliconoma),
and discharging sinuses (Fig. 2). Nowadays, either fixed-
volume silicone gel-filled implants or adjustable-volume
saline-filled implants are most commonly used.88 In some
countries, soft tissue fillers such as polyacrylamide hydro-
gel have also been used in breast augmentation procedures.
Infective complications of breast augmentation may be
classified into early and late infections. An overall inci-
dence of 2.5% is often quoted, with acute postoperative
infection accounting for 1.7% and late infection for 0.8%.88
Infections that occurred after 1 month postoperatively are
usually considered to be “late” infections. The risk of
infection is much higher (up to 10 times) in patients
undergoing reconstructive surgery as compared to in those
undergoing aesthetic surgery because the former group of
patients have a higher incidence of underlying (systemic
and local) comorbidities, prior chemotherapy and radio-
therapy, and a greater degree of local tissue trauma.22,89
The use of human acellular dermal matrix for cosmetic
breast augmentation is associated with a higher risk of
infection (relative risk 2.47) and other complications as
compared to conventional submuscular reconstructions.28
The routes of infection for breast implants are similar to
those for other implants such as joint prostheses and heart
valves. Infection can result from the use of contaminated
prostheses or saline (in the case of saline-filled implants),
microbial contamination of the surgical site during surgery,
or seeding from distant infective foci. On rare occasions,
contaminated gentian violet skin-marking solution led to an
outbreak of Mycobacterium abscessus surgical wound
infection after cosmetic surgery.23
The breast glandular tissues are not sterile, as the ducts
are colonized by normal flora of the skin. Such microbes are
the commonest cause of acute postoperative infections.
S. aureus is the predominant pathogen, with beta-hemolytic
streptococci and fast growing atypical mycobacteria being
important causes as well.24,90,91 Late infections are often
secondary to episodes of bacteremia and distant infections;
cases due to S. aureus, coagulase-negative staphylococci,
P. aeruginosa, Pasteurella multocida, Bacteroides fragilis,
Enterococcus, and Klebsiella pneumoniae have been
reported.88
The optimal pharmacological prophylaxis of breast
implant infections is not completely clear, and current
Figure 2 A 64-year-old lady had received bilateral breast augmentation surgery with silicone gel prosthesis in her early years. (A)
She developed extensive inflammation, scarring, and cavity formation over bilateral chest wall with sternal and costal osteomy-
elitis. (B) Rupture of the prostheses was evident upon removal. (C) Histopathology of the surrounding tissues revealed multiple,
large vacuolated areas (original magnification, 100). (D) Grocott stain of the tissues showed numerous septate branching hyphae
(original magnification, 1000), culture of which yielded Aspergillus spp.
676 S.S.-Y. Wong et al.practice varies greatly among different centers due to the
lack of large randomized controlled trials. Local irrigation,
using povidone-iodine, bacitracin, povidone-iodine/
cefazolin/gentamicin, or bacitracin/cefazolin/gentamicin,
has been performed.92e94 Preoperative prophylactic anti-
biotics are useful for preventing surgical site infection in
patients undergoing breast surgery.95 The most commonly
used antibiotics are penicillins with antistaphylococcal
activities, first-generation cephalosporins, and beta-
lactam/beta-lactamase inhibitor combinations; patients
with beta-lactam allergy generally receive macrolides or
clindamycin. The role of postoperative antibiotic prophy-
laxis in breast augmentation surgery is more contentious. In
some studies, no benefits have been found after giving
antibiotics for 3 postoperative days in primary or secondary
breast augmentation, whereas other studies have advo-
cated the use of more prolonged postoperative prophylaxis
in breast reconstruction patients who required implants,
especially in those who had received chemotherapy and/or
radiotherapy after surgery.94,96,97
Injectable permanent soft tissue fillers, such as poly-
acrylamide hydrogel, for breast augmentation was first
used in Ukraine, subsequently gaining popularity in China.
The polymer is considered to be nontoxic, nonbiodegrad-
able, and nonteratogenic.98 Some claimed that tissue
response to the polyacrylamide polymer is moderate to
minimal with little fibrosis, but others reported dense
fibrous tissue formation with inflammation.98,99 In contrast
to the small amount being used in facial augmentation,
large volumes (up to 200 mL or more) of polyacrylamide
hydrogel are used in breast augmentation. Adverse reac-
tions to polyacrylamide polymer following its use in breastaugmentation were first observed in 1997.31 Since then
a number of complications, such as multiple induration,
palpable lumps, mastalgia, lactorrhea, disfigurement,
migration of implant, and infection, were reported.31e35,100
Infection has been quoted in most series as a complication
(incidence ranged from 4% to 27%), but its detailed course
and causative agents were not described.Mesotherapy, liposuction, tissue filler
injections, and other procedures
Subcutaneous injection therapy, also known as meso-
therapy, using phosphatidylcholine or other agents (such as
isoproterenol), has become a popular method for body
contouring in some countries, although the efficacy of such
procedures has not been confirmed scientifically.101,102 By
far, the commonest pathogens causing infections after
mesotherapy are atypical mycobacteria, especially the
rapid growers such as M. chelonae and M. abscessus, and
outbreaks are being reported regularly.37e43,103,104 The use
of contaminated injection materials and tap water for
cleaning instruments has been associated with outbreaks of
infection.39,41,42 Similarly, the rapid growers are often
involved in infections associated with liposuction.44,105e107
Indeed, a number of novel Mycobacterium species have
been described in recent years in cases of infections
acquired after body modification or cosmetic procedures,
such as M. cosmeticum, M. jacuzzii, M. massiliense, and
M. bolletii.24,108,109 In addition, other environmental
pathogens such as Nocardia and Sporothrix schenckii are
associated with such procedures.110,111 It is therefore
Infections associated with body modification 677imperative that patients who have developed infection
after body modifications should be investigated for such
mycobacterial, nocardial, and fungal etiologies, in addition
to routine bacteriological studies.
In recent years, the use of dermal filler injections for
soft tissue (especially facial) augmentation has gained
popularity in many parts of the world. Although the
procedure is generally safe, associated infective compli-
cations are not unheard of.112e114 Chronic mandibular
osteomyelitis has been reported to complicate facial
augmentation using polyacrylamide hydrogel.115 Unlike in
other conventional prosthesis-related infections, complete
removal of the injected fillers may not be possible, and
hence a more prolonged course of antibiotics may be
necessary in some situations.
More recently, new procedures have been used in some
developed countries for their purported cosmetic or health
benefits. One example is the so-called “cell therapy”,
which involves the injection of cells of animal or human
origin or extracts of animal tissues. In addition to the lack
of any scientific basis for their therapeutic claims, the
potential health risks of such “therapies” are unknown.
Transmission of zoonotic pathogens is one theoretical
possibility, but a real threat is the transmission of bacterial
pathogens through contaminations during the procedure. In
a recent outbreak in Hong Kong, at least four customers
who had received “cytokine-induced killer cell therapy”
(intravenous infusion of the customers’ own leukocytes
after a period of ex vivo incubation) at a beauty treatment
center developed severe septic shock caused by
M. abscessus.116 At least one patient died as a result of the
infection. Although the exact mode of contamination
remains to be investigated at the time of writing, this
incident highlights the importance of stricter public health
control on these potentially dangerous procedures.General approach to diagnosis and therapy
The presentation of body modification-related infections
falls into three major categories: infections caused by
bloodborne pathogens (mainly viruses such as HBV, HCV,
and HIV); local infections at the sites of tattoo, piercing,
surgery, or injections; and metastatic or disseminated
infections. Patients who had received body modifications
should alert the clinician to these associated infections.
Conversely, in patients with aforementioned infections but
with unexplained origins, body modification procedures
should be enquired as possible predisposing factors. This is
not only clinically important for the individual patients, but
also significant from the public health perspective. Initial
cases may represent the few most severe victims, and
further investigations and case findings may unravel a silent
outbreak in the community. Prompt control measures by
the health authorities are crucial to prevent the occurrence
of new cases.
The clinical diagnosis of local or systemic infections is
generally not difficult for most clinicians. The timing and
nature of specific microbiological investigations are crucial
for more serious cases. In otherwise uncomplicated infec-
tions, such as cellulitis or local abscesses, patients are
frequently managed in the primary health-care setting withempirical antibiotics and/or drainage, often without
microbial cultures. First-line empirical antibiotics with
beta-lactam/beta-lactamase inhibitor combinations (such
as co-amoxiclav or ampicillinesulbactam) or first- and
second-generation cephalosporins (such as cephalexin,
cefazolin, or cefuroxime) should cover the common
commensal flora, including staphylococci, beta-hemolytic
streptococci, and some Enterobacteriaceae (especially in
the case of genital piercing). Infections in the oral cavity or
pelvic regions, or specific syndromes such as Lemierre’s
syndrome should be treated with antibiotics with anaerobic
coverage (beta-lactam/beta-lactamase inhibitor combina-
tions or adding metronidazole to the cephalosporin regi-
mens). Severe or systemic infections or those that do not
respond to standard treatments should always be accom-
panied by appropriate microbiological investigations. This
is important not only for the diagnosis of fungal, nocardial,
and mycobacterial pathogens, but also for excluding
antibiotic-resistant pathogens such as P. aeruginosa and
community-associated methicillin-resistant S. aureus that
is prevalent in many parts of the world.
Acid-fast staining, and mycobacterial and fungal
cultures should be performed in nonresponding cases. Pus
specimens or skin biopsies should be performed in patients
presenting with nodular or pustular lesions suggestive of
atypical mycobacterial infections. Additionally, histological
examination of the biopsy samples is needed since some
fungal or mycobacterial pathogens may require prolonged
incubation for growth or may not be readily cultivable in
routine culture media. The presence of these microbes and
the type of inflammatory response may help establish the
preliminary diagnosis and guide empirical therapy.
Patients with suspected breast implant infections should
undergo ultrasonographic or computed tomography exami-
nation, and any collection should be aspirated for micro-
biological investigations, including Gram and acid-fast
stain, and routine bacterial and mycobacterial cultures.
Surgical removal of the implant should ideally be per-
formed, and a 2-week course of antibiotic has to be
advocated.88 Antibiotics such as co-amoxiclav, ampi-
cillinesulbactam, or a first- or second-generation cephalo-
sporin will cover most of the common pathogens, while
antibiotics with antipseudomonal activities should be used
for patients with documented P. aeruginosa infection.
Immediate reimplantation is not advisable.Prevention and regulation
Preventive measures can reduce but not abrogate all the
risks of infection associated with body modification.
Infections by endogenous flora of the skin and mucosae
after body piercing cannot be prevented completely, given
that the wounds take a long time to heal and that foreign
bodies are present. Prevention of exogenous infections
requires proper skin antisepsis prior to the procedures,
adequate disinfection of all instruments and the operating
field, hand hygiene, use of standard precautions, avoiding
the presence of pet animals and plants in the premises, and
proper choice and maintenance of antiseptics, disinfec-
tants, and sterilization techniques. Improper choices,
dilutions, and topping up of chemical disinfectants as well
678 S.S.-Y. Wong et al.as their use beyond the expiry dates constitute a recipe for
disaster. Contamination of disinfectants by environmental
bacteria is well documented, and such incidents can lead to
outbreaks of infections.8 P. aeruginosa is a frequent culprit,
although bacteria such as other Pseudomonas spp., Bur-
kholderia spp. (especially B. cepacia), Serratia marcescens,
and atypical mycobacteria can also be involved.117 Atypical
mycobacteria can often be found in tap water, and the sole
use of tap water for cleaning of mesotherapy instruments
has been reported to lead to the outbreaks of cutaneous
mycobacterial infections.41,42
In many developed countries, guidelines or codes of
practice are available for body art practitioners and parlors
to reduce the risk of transmission of infection.118e121
However, these regulations are not always legally binding.
Body modification practitioners and tattooists likewise have
been found to have inadequate training, insufficient
knowledge of infection control, and poor compliance to
proper safety precautions.121e124 Activities such as more
stringent inspections, providing adequate educating, and
more feedback activities have to be carried out by the
regulatory authorities in this often-overlooked field to
minimize the risk of infection and other health
problems.125,126Conclusion
Body modification is a popular form of body art in many
parts of the world. Various patient- and procedure-related
factors may predispose individuals to the development of
local and systemic infections. Individuals must be made
aware of the health risks prior to undergoing any such
procedure, and medical practitioners should be aware of
the infective and noninfective complications associated
with these procedures. Patients with infections not
responding to conventional antibacterial coverage should
be investigated for pathogens such as atypical mycobac-
teria, nocardiae, and fungi. More importantly, lapses in
infection control and disinfection procedures have
frequently been found to result in outbreaks of infections.
Stricter regulations and inspections of operators by the
health authorities are necessary to reduce the risks, and
the medical practitioners, who play an important role in
the surveillance of disease activity, should have a high
index of suspicion for identifying such outbreaks, especially
when outbreak-associated pathogens such as atypical
mycobacteria or pseudomonads are isolated.References
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